“…The vast majority of SNHL results from the loss of sensory hair cells (HCs), which, in mature mammalian cochleae, do not regenerate (McGill and Schuknecht, 1976; Soucek et al, 1986). Recently, research aimed at regenerating HCs has focused on ATOH1, a basic helix-loop-helix (bHLH) transcription factor that represents a therapeutic target for converting nonsensory supporting cells (SCs) into sensory HCs (Atkinson et al, 2014; Chen et al, 2013; Izumikawa et al, 2008; Izumikawa et al, 2005; Kawamoto et al, 2003; Kelly et al, 2012; Kraft et al, 2013; Kuo et al, 2015; Liu et al, 2012; Liu et al, 2014; Ouji et al, 2013; Pan et al, 2013; Parker et al, 2014; Wu et al, 2013; Yang et al, 2012; Yang et al, 2013; Zhao et al, 2011; Zheng and Gao, 2000). Indeed, clinical trials are being conducted to test whether an ATOH1 gene therapy can rehabilitate hearing in SNHL patients (Novartis-Pharmaceuticals).…”